Insider Trading Alert - WPZ, UVV, MDAS, GILD And ENH Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Nov. 8, 2013, 143 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $296.78 to $400,200,000.00.

Highlighted Stocks Traded by Insiders:

Williams Partners (WPZ) - FREE Research Report

Karam Thomas F who is Director at Williams Partners sold 23,000 shares at $50.01 on Nov. 8, 2013. Following this transaction, the Director owned 130,297 shares meaning that the stake was reduced by 15% with the 23,000 share transaction.

The shares most recently traded at $49.50, down $0.51, or 1.03% since the insider transaction. Historical insider transactions for Williams Partners go as follows:

  • 12-Week # shares sold: 20,000
  • 24-Week # shares sold: 26,000

The average volume for Williams Partners has been 652,000 shares per day over the past 30 days. Williams Partners has a market cap of $22.0 billion and is part of the basic materials sector and chemicals industry. Shares are up 3.08% year to date as of the close of trading on Friday.

Williams Partners L.P., an energy infrastructure company, focuses on connecting North America's hydrocarbon resource plays to growing markets for natural gas and natural gas liquids (NGL). It operates in two segments, Gas Pipeline and Midstream Gas & Liquids. The stock currently has a dividend yield of 7%. The company has a P/E ratio of 28.5. Currently there are 7 analysts that rate Williams Partners a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WPZ - FREE

TheStreet Quant Ratings rates Williams Partners as a buy. The company's strengths can be seen in multiple areas, such as its good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Williams Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Universal Corporation (UVV) - FREE Research Report

Johnson Thomas H who is Director at Universal Corporation sold 1,425 shares at $50.33 on Nov. 8, 2013. Following this transaction, the Director owned 15,407 shares meaning that the stake was reduced by 8.47% with the 1,425 share transaction.

The shares most recently traded at $50.71, up $0.38, or 0.75% since the insider transaction. Historical insider transactions for Universal Corporation go as follows:

  • 12-Week # shares sold: 925
  • 24-Week # shares sold: 21,611

The average volume for Universal Corporation has been 212,900 shares per day over the past 30 days. Universal Corporation has a market cap of $1.2 billion and is part of the consumer goods sector and tobacco industry. Shares are up 0.3% year to date as of the close of trading on Friday.

Universal Corporation, through its subsidiaries, operates as a leaf tobacco merchant and processor worldwide. It engages in selecting, procuring, processing, packing, storing, shipping, and financing leaf tobacco for sale to, or for the account of, manufacturers of consumer tobacco products. The stock currently has a dividend yield of 4.08%. The company has a P/E ratio of 9.8. Currently there is 1 analyst that rates Universal Corporation a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on UVV - FREE

TheStreet Quant Ratings rates Universal Corporation as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow. Get the full Universal Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

MedAssets (MDAS) - FREE Research Report

Bardis John A who is Chairman, President and CEO at MedAssets sold 200,000 shares at $22.04 on Nov. 8, 2013. Following this transaction, the Chairman, President and CEO owned 800,777 shares meaning that the stake was reduced by 19.98% with the 200,000 share transaction.

The shares most recently traded at $21.73, down $0.31, or 1.42% since the insider transaction. Historical insider transactions for MedAssets go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 21,305
  • 24-Week # shares sold: 116,527

The average volume for MedAssets has been 452,000 shares per day over the past 30 days. MedAssets has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 29.82% year to date as of the close of trading on Friday.

MedAssets, Inc., a financial and performance improvement company, provides technology-enabled products and services for hospitals, health systems, and other ancillary healthcare providers in the United States. The company has a P/E ratio of 311.0. Currently there are 8 analysts that rate MedAssets a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDAS - FREE

TheStreet Quant Ratings rates MedAssets as a hold. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and weak operating cash flow. Get the full MedAssets Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Gilead (GILD) - FREE Research Report

Washington Robin L who is Svp, Cfo at Gilead sold 2,869 shares at $68.63 on Nov. 8, 2013. Following this transaction, the Svp, Cfo owned 22,826 shares meaning that the stake was reduced by 11.17% with the 2,869 share transaction.

The shares most recently traded at $67.74, down $0.89, or 1.32% since the insider transaction. Historical insider transactions for Gilead go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 12,000
  • 24-Week # shares sold: 24,000

The average volume for Gilead has been 7.7 million shares per day over the past 30 days. Gilead has a market cap of $100.6 billion and is part of the health care sector and drugs industry. Shares are up 78.71% year to date as of the close of trading on Friday.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. The company has a P/E ratio of 36.1. Currently there are 15 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GILD - FREE

TheStreet Quant Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Endurance Specialty Holdings (ENH) - FREE Research Report

Charman John who is Chmn & Chief Executive Officer at Endurance Specialty Holdings bought 25,700 shares at $36.52 on Nov. 8, 2013. Following this transaction, the Chmn & Chief Executive Officer owned 770,390 shares meaning that the stake was reduced by 3.45% with the 25,700 share transaction.

The shares most recently traded at $56.66, up $20.14, or 35.54% since the insider transaction. Historical insider transactions for Endurance Specialty Holdings go as follows:

  • 12-Week # shares bought: 39
  • 12-Week # shares sold: 12,737
  • 24-Week # shares bought: 4,544
  • 24-Week # shares sold: 481,140

The average volume for Endurance Specialty Holdings has been 191,800 shares per day over the past 30 days. Endurance Specialty Holdings has a market cap of $2.5 billion and is part of the financial sector and insurance industry. Shares are up 40.84% year to date as of the close of trading on Friday.

Endurance Specialty Holdings Ltd. underwrites specialty lines of personal and commercial property and casualty insurance and reinsurance worldwide. The company operates in two segments, Insurance and Reinsurance. The stock currently has a dividend yield of 2.29%. The company has a P/E ratio of 13.6. Currently there is 1 analyst that rates Endurance Specialty Holdings a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENH - FREE

TheStreet Quant Ratings rates Endurance Specialty Holdings as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Endurance Specialty Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Dow Futures Plunge, Global Markets Rocked as Trump Takes Trade War to Next Level

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Trump Threatens More Tariffs and 4 Other Stories to Watch Tuesday Morning

Trump Threatens More Tariffs and 4 Other Stories to Watch Tuesday Morning

Trump Issues New Trade Threats, Apple, ZTE, GameStop - 5 Things You Must Know

Trump Issues New Trade Threats, Apple, ZTE, GameStop - 5 Things You Must Know

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats

China-Focused Stocks Hit Hard as Beijing Responds to Trump Tariff Threats